Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
What is the risk of interaction between opioid analgesics and monoamine oxidase inhibitors (MAOIs)?

Publisher: South West Medicines Information and Training

Date published: 02/02/2009 14:29

Expires on: 05/01/2011 14:29

Summary
by: Jenny Haylor
  • The use of most MAOIs with opioids is contraindicated by most, but not all manufacturers. (There are significant variations between UK and US literature).

 

  • Pethidine is the only commonly used opioid to have been reported to cause serotonin syndrome when used with MAOIs.

 

  • Some opioid analgesics are associated with a risk of serotonin syndrome in combination with MAOIs due to inhibition of serotonin re-uptake. Other combinations may result in opioid toxicity due to CYP450 enzyme inhibition by the MAOI.

 

  • Any trials conducted in this field are not recent and measure different outcomes from those now included in the definition of serotonin syndrome. This means almost all information is based on case reports.

 

  • Morphine is a widely recommended alternative to pethidine in patients receiving MAOIs, though starting at a low dose and titrating to clinical response would be advised. The patient should be monitored for signs of opioid toxicity.
UKMi_QA192_1_final.doc
Related evidence
4.3.1 Tricyclic and related antidepressant drugs
23/09/2008
S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies
19/07/2007
Amitriptyline for depression
18/12/2006
Lithium versus antidepressants in the long-term treatment of unipolar affective disorder
4.3.2 Monoamine-oxidase inhibitors (MAOIs)
02/02/2005
Depression: management of depression in primary and secondary care
4.3.3 Selective serotonin re-uptake inhibitors
03/02/2010
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors
15/09/2009
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
24/06/2009
Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis
4.3.4 Other antidepressant drugs
19/01/2010
Cochrane review: Milnacipran versus other antidepressive agents for depression
15/12/2009
MTRAC verdict and summary: Agomelatine for major depressive episodes
15/12/2009
MTRAC verdict and summary: Duloxetine for GAD
4.7.2 Opioid analgesics
15/12/2009
CKS topic review: Restless legs syndrome
10/11/2009
SMC accepts restricted use of fentanyl nasal spray (Instanyl®) in NHSScotland
05/11/2009
MTRAC verdict: Oxycodone + naloxone in severe pain
4.9.1 Dopaminergic drugs used in parkinsonism
14/09/2009
AWMSG accepts prolonged-release ropinirole (Requip XL®) for the treatment of idiopathic Parkinson’s disease
12/08/2009
SMC accepts rotigotine (Neupro™) for treatment of moderate to severe idiopathic restless legs syndrome in adults
25/11/2008
Levodopa for idiopathic restless legs syndrome: evidence-based review
Back